Company: KROS
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001664710-25-000089
Chunk: 239

Company: Keros Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 239
---
 — — — Effect of potentially dilutive restricted stock units— — 179,252 — Total potentially dilutive securities— — 603,594 — Weighted-average shares of common stock outstanding used to compute diluted net loss140,623,364 37,590,727 41,202,371 36,463,906 Net income (loss) per share of common stockBasic$(0.18)$(1.41)$2.72 $(3.88)Diluted$(0.18)$(1.41)$2.68 $(3.88)The Company excluded the following from the computation of diluted net income (loss) per share attributable to common stockholders as of September 30, 2025 and 2024 because including them would have had an anti-dilutive effect:THREE MONTHS ENDED SEPTEMBER 30,NINE MONTHS ENDED SEPTEMBER 30,2025202420252024RSU awards55,087 — 18,564 — Options to purchase common stock4,407,885 5,257,234 4,711,081 5,257,234 Employee stock purchase plan shares8,976 34,466 8,976 34,466 Total4,471,948 5,291,700 4,738,621 5,291,700 

9. INCOME TAXES 

The Company calculates income taxes at each interim reporting period based on the estimated annual effective tax rate for the full year, adjusted for any discrete events which are recorded in the period they occur. Cumulative adjustments to the income tax provision are recorded in the interim reporting period in which a change in the estimated annual effective tax rate is determined. The Company’s income tax (provision) benefit and effective tax rate are presented below (income tax (provision) benefit in thousands):THREE MONTHS ENDED SEPTEMBER 30,NINE MONTHS ENDED SEPTEMBER 30,2025202420252024Income tax (provision) benefit1,424 — (6,397)— Effective tax rate(16.4)%— %5.5 %— %The increase in the income tax (provision) benefit and the effective tax rate for the three and nine months ended September 30, 2025 is primarily due to taxable income during the period resulting from the Takeda Agreement